JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 46(2012) N 6 p. 780-789;
N.V. Gubanova1,2*, A.S. Gaytan3, I.A. Razumov1,2,4, V.A. Mordvinov1, A.L. Krivoshapkin1,3, S.V. Netesov2,4, P.M. Chumakov2,5,6

Oncolytic Viruses in the Therapy of Gliomas

1Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090
2Novosibirsk State University, Novosibirsk, 630090
3Meshalkin Institute of Circulation Pathology, Novosibirsk, 630055
4State Research Center of Virology and Biotechnology "Vector", Koltsovo, 630559
5Cleveland Clinic Foundation, Cleveland, 41195, USA
6Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991

*nat@bionet.nsc.ru
Received - 2012-05-28; Accepted - 2012-06-14

Despite the modern advances in medicine, cure for malignant glioblastomas remains an elusive goal. Both the invasive nature and the location in vital areas of the brain make this type of tumors difficult to treat surgically, while adjuvant therapy fails to bring the expected results. Frequent recurrence and invasiveness of malignant gliomas are due to the resistance of glioma stem cells to conventional radiation therapy and chemotherapy. Technological achievements in constructing recombinant viruses yielded strains with high oncolytic activity toward glial tumors. Many of these strains have passed Phase I clinical studies and proved to be highly safe. Although the approach is obviously promising, the available strains are not efficacious enough to cure the disease and need further improvement. The review summarizes the results reported for the most successful variants of oncolytic viruses that have come down to clinical trials and discusses the prospects of new approaches to viral therapy of malignant gliomas.

gliomas, oncolytic viruses, antitumor therapy, molecular oncology



JMB-FOOTER RAS-JOURNALS